« Back |
Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting |
![]() |
“We are an emerging multi-product company, advancing a substantial
pipeline of targeted therapies for patients with solid tumors and blood
cancers,” said Abstracts can be found at www.aacr.org and include the following:
About
Forward-Looking Statements
Certain of the statements made in this press release are
forward-looking, such as those, among others, relating to the possible
utility or application of the Company’s technologies to develop
therapeutic agents, therapeutic potential of investigational agents, and
future development activities including clinical trials. Actual results
or developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include the difficulty and uncertainty of pharmaceutical
product development, including the risks that
View source version on businesswire.com: https://www.businesswire.com/news/home/20180412005347/en/ Source:
Seattle Genetics, Inc. |